Clinical trials in ovarian carcinoma: Study methodology

Annals of Oncology

Volumn 16, Issue SUPPL. 8, 2005, Pages

  Vermorken, Jan B ^a,b   Parmar, M K B ^a   Brady, M F ^a   Eisenhauer, E A ^a   Hogberg, T ^a   Ozols, R F ^a   Rochon, J ^a   Rustin, G J S ^a   Sagae, S ^a   Verheijen, R H M ^a  

^a EORTC ^*  (Japan)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TRASTUZUMAB;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; MAINTENANCE THERAPY; MEDICAL ETHICS; META ANALYSIS; METHODOLOGY; OVARY CARCINOMA; PAGET NIPPLE DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 27744572708     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi963     Document Type: Conference Paper

References (52)

1. Sylvester R. Planning cancer clinical trials. In Buyse ME, Staquet MJ, Sylvester RJ (eds): Oxford Cancer Clinical Trials - Methods and Practice. 47-63. Oxford University Press 1982.
2. Brady MF, Thigpen JT, Vermorken JB, Parmar MKB. Randomised trials in ovarian cancer: Trial design considerations. Ann Oncol 1999; 10 (Suppl 1): S75-S82.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-2529.
4. Berek JS, Bertelsen K, du Bois A et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10 (Suppl 1): S87-S92.
5. Vergote I, De Brabanter J, Fyles A et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357: 176-182.
6. Zanetta G. The accuracy of staging: An important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. Ann Oncol 1998; 9: 1097-1101.
7. Eisenhauer EA, Gore M, Neijt JP. Ovarian cancer: Should we be managing patients with good and bad prognostic factors in the same manner? Ann Oncol 1999; 10 (Suppl 1): S9-S15.
8. Tropé C, Kaern J, Hogberg T et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 2000; 11: 281-288.
9. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: An analysis of 704 patients. Ann Oncol 1997; 8: 963-968.
10. van Glabbeke M, Vermorken J, Eisenhauer E. Predictors of survival (OS) and time to progression (TTP) following 2nd and 3rd line treatment in advanced ovarian cancer (OVCA): An analysis of 744 patients (pts) treated with paclitaxel, docetaxel, or high dose epirubicin. Proc Am Soc Clin Oncol 1997; 16: 254a (Abstr 1265).
11. ICON1 and EORTC-ACTION Collaborators. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant Chemotherapy In Ovarian Neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-112.
12. Bell J, Brady M, Lage J et al. A randomized trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2003; 88: 156 (Abstr 1).
13. International Collaborative Ovarian Neoplasm (ICON1) Collaborators. International Collaborative Ovarian Neoplasm Trial 1: A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003; 95: 125-132.
14. Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organization for Research and treatment of Cancer - Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 2003; 95: 113-125.
15. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
16. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2000; 18: 106-115.
17. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-1955.
18. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001-1007.
19. Amstrong DK, Bundy BN, Baergen R et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 172). Proc Am Soc Clin Oncol 2002; 21: 201a (Abstr 803).
20. Piccart MJ, Floquet A, Scarfone G et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 2003; 13 (Suppl 2): 196-203.
21. Bookman MA, Darcy KM, Clarke-Pearson D et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 283-290.
22. Royston P, Parmar MKB, Qian W. Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat Med 2003; 22: 2239-2256.
23. UK Coordinating Committee on Cancer Research (UKCCCR) Ductal Carcinoma In Situ (DCIS) Working Party. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: Randomized controlled trial. Lancet 2003; 362: 95-102.
24. Law MG, Emery S. Selective exclusion of treatment arms in multi-arm randomized clinical trials. Stat Med 2003; 22: 19-30.
25. Hochberg Y, Tamhane AC. Multiple Comparison Procedures. New York: John Wiley and Sons 1987.
26. Dunnett CW, Tamhane AC. A step up multiple test procedure. J Am Stat Assoc 1992; 87: 162-170.
27. Proschan MA, Follman DA. Multiple comparisons with control in a single experiment: Why do we feel differently? Am Stat 1995; 49: 144-149.
28. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: Are we being misled? Ann Int Med 1994; 125: 605-613.
29. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
30. Thiesse P, Olivier L, Di Stefano-Louineau D et al. Response rate accuracy in oncology trials: Reasons for interobserver variability. J Clin Oncol 1997; 15: 3507-3514.
31. Rustin GJ. Use of CA125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21 (Suppl 10): 187-193.
32. Rustin GJS, Quinn M, Thigpen T et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004; 96: 487-488.
33. Guastalla J, Vincent P, Le Rol A et al. CA-125 evaluation of chemotherapy response in patients with recurrent ovarian cancer (ROC). Proc Am Soc Clin Oncol 2002; 21: 204a (Abstr 815).
34. Lakusta CM, Atkinson MJ, Robinson JW et al. Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol Oncol 2001; 81: 490-495.
35. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
36. Vergote I, Rustin GJS, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2000; 92: 1543-1545.
37. Nabholtz JM, Vannetzel JM, Llory JF, Boufette P. Advances in the use of taxanes in the adjuvant therapy of breast cancer. Clin Breast Cancer 2003; 4: 187-192.
38. Piccart MJ, Bertelsen K, James K et al. Randomized trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000; 92: 699-708.
39. International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 2002; 360: 505-515.
40. du Bois A, Combe J, Rochon C et al. Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stage IIB-IV. An AGO-GINECO Intergroup phase III trial. J Clin Oncol 2004; 22: 450 (Abstr 5007).
41. De Placido S, Scambia G, Di Vagno G et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian cancer (MITO-1) randomized study. J Clin Oncol 2004; 22: 2635-2642.
42. Buyse M, Molenberghs G, Burzykowski T et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1: 49-67.
43. Ovarian Cancer Meta-analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 1991; 9: 1668-1674.
44. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-2666.
45. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin (GC) vs carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol 2004; 22: 450 (Abstr 5005).
46. du Bois A, Meier W, Luck HJ et al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: A randomized trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 2002; 13: 251-257.
47. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-2193.
48. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-2465.
49. Cannistra S. The eithics of early stopping rules: Who is protecting whom? J Clin Oncol 2004; 22: 1542-1545.
50. Perulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice. J Natl Cancer Inst 2004; 96: 990-997.
51. Hall GD, Brown JM, Coleman RE et al. Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer 2004; 91: 621-626.
52. Biagi JJ, Eisenhauer EA. Systemic treatment policies in ovarian cancer: the next 10 years. Int J Gynecol Cancer 2003; 13 (Suppl 2): 231-240.